266 related articles for article (PubMed ID: 19930182)
1. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
Barosi G; Birgegard G; Finazzi G; Griesshammer M; Harrison C; Hasselbalch H; Kiladijan JJ; Lengfelder E; Mesa R; Mc Mullin MF; Passamonti F; Reilly JT; Vannucchi AM; Barbui T
Br J Haematol; 2010 Mar; 148(6):961-3. PubMed ID: 19930182
[No Abstract] [Full Text] [Related]
2. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
Löfvenberg E; Wahlin A
Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824
[TBL] [Abstract][Full Text] [Related]
3. [The therapy of hemoblastosis and malignant lymphoma. I. Leukosis, polycythemia vera and osteomyelosclerosis].
Löffler H; Schultis K
Med Welt; 1968 Jan; 1():96-100. PubMed ID: 5704123
[No Abstract] [Full Text] [Related]
4. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera.
Alvarez-Larrán A; Kerguelen A; Hernández-Boluda JC; Pérez-Encinas M; Ferrer-Marín F; Bárez A; Martínez-López J; Cuevas B; Mata MI; García-Gutiérrez V; Aragües P; Montesdeoca S; Burgaleta C; Caballero G; Hernández-Rivas JA; Durán MA; Gómez-Casares MT; Besses C;
Br J Haematol; 2016 Mar; 172(5):786-93. PubMed ID: 26898196
[TBL] [Abstract][Full Text] [Related]
5. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.
Fruchtman SM; Mack K; Kaplan ME; Peterson P; Berk PD; Wasserman LR
Semin Hematol; 1997 Jan; 34(1):17-23. PubMed ID: 9025158
[No Abstract] [Full Text] [Related]
6. [Hydroxyurea-induced pneumonitis].
Schwonzen M; Spangenberger H; Spengler M
Med Klin (Munich); 2003 Jul; 98(7):394-7. PubMed ID: 12937905
[TBL] [Abstract][Full Text] [Related]
7. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
8. Hypereosinophilic syndrome associated with polycythemia vera.
Varon D; Wetzler M; Berrebi A
Arch Intern Med; 1986 Jul; 146(7):1440-1. PubMed ID: 3718142
[TBL] [Abstract][Full Text] [Related]
9. [Black discoloration of nails in polycythaemia vera].
Konrad H; Wollina U
J Dtsch Dermatol Ges; 2005 Sep; 3(9):723-5. PubMed ID: 16173981
[No Abstract] [Full Text] [Related]
10. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
Alvarez-Larrán A; Pereira A; Cervantes F; Arellano-Rodrigo E; Hernández-Boluda JC; Ferrer-Marín F; Angona A; Gómez M; Muiña B; Guillén H; Teruel A; Bellosillo B; Burgaleta C; Vicente V; Besses C
Blood; 2012 Feb; 119(6):1363-9. PubMed ID: 22160617
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.
Harrison CN; Griesshammer M; Miller C; Masszi T; Passamonti F; Zachee P; Durrant S; Pane F; Guglielmelli P; Verstovsek S; Jones MM; Hunter DS; Sun W; Li J; Khan M; Habr D; Kiladjian JJ
Br J Haematol; 2018 Jul; 182(2):279-284. PubMed ID: 29984424
[No Abstract] [Full Text] [Related]
12. Management of polycythemia vera with hydroxyurea.
Tatarsky I; Sharon R
Semin Hematol; 1997 Jan; 34(1):24-8. PubMed ID: 9025159
[No Abstract] [Full Text] [Related]
13. Hydroxycarbamide associated platelet count oscillations in a patient with polycythaemia vera. A case report and review of the literature.
Burthem J; Chaudhry MS
Platelets; 2008 May; 19(3):234-5. PubMed ID: 18432524
[TBL] [Abstract][Full Text] [Related]
14. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.
Barosi G; Besses C; Birgegard G; Briere J; Cervantes F; Finazzi G; Gisslinger H; Griesshammer M; Gugliotta L; Harrison C; Hasselbalch H; Lengfelder E; Reilly JT; Michiels JJ; Barbui T
Leukemia; 2007 Feb; 21(2):277-80. PubMed ID: 17251900
[TBL] [Abstract][Full Text] [Related]
15. [On the effect of a new cytostatic drug in chronic myeloses and polycythemias].
Böhnel J; Stacher A
Wien Med Wochenschr; 1968 Sep; 118(37):721-3. PubMed ID: 5248360
[No Abstract] [Full Text] [Related]
16. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
17. [Hydroxyurea induced-leg ulcer in polycythemia vera].
Khaled A; El Guellali N; Aissaoui L; Robbana F; Ezzine N; Fazaa B; Kamoun MR
Tunis Med; 2011 Mar; 89(3):292-4. PubMed ID: 21387237
[TBL] [Abstract][Full Text] [Related]
18. A review of the therapeutic agents used in the management of polycythaemia vera.
McMullin MF
Hematol Oncol; 2007 Jun; 25(2):58-65. PubMed ID: 17352450
[TBL] [Abstract][Full Text] [Related]
19. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.
Hernández-Boluda JC; Alvarez-Larrán A; Gómez M; Angona A; Amat P; Bellosillo B; Martínez-Avilés L; Navarro B; Teruel A; Martínez-Ruiz F; Besses C
Br J Haematol; 2011 Jan; 152(1):81-8. PubMed ID: 21083657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
